Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Cummings, Steven R., Martin, Javier San, McClung, Michael R., Siris, Ethel S., Eastell, Richard, Reid, Ian R., Delmas, Pierre, Zoog, Holly B. +8 more·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0809493

Cited by (1,006)

Items 601–700 of 1,006

  1. Treatment Sequence for Osteoporosis
    Felicia Cosman, Bente Lomholt Langdahl, Benjamin Z. Leder · 2024 · Endocrine Practice
  2. Osteoclastic bone resorption induced by innate immune responses
    Masanori Koide, Saya Kinugawa, Naoyuki Takahashi, Nobuyuki Udagawa · 2010 · Periodontology 2000
  3. Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW)
    Adolfo Díez‐Pérez, Jonathan Derrick Adachi, Silvano Adami, Frederick A. Anderson, Steven Boonen, Roland D Chapurlat, Juliet Elizabeth Compston, Cyrus C. Cooper, Stephen H. Gehlbach, Susan L. Greenspan et al. · 2013 · Journal of Bone and Mineral Research
  4. RANKL/RANK – From bone physiology to breast cancer
    Verena Sigl, Josef Martin Penninger · 2014 · Cytokine & Growth Factor Reviews
  5. Minor, Major, Low-Trauma, and High-Trauma Fractures: What Are the Subsequent Fracture Risks and How Do They Vary?
    Amy H. Warriner, Nivedita M. Patkar, Huifeng Yun, Elizabeth Delzell · 2011 · Current Osteoporosis Reports
  6. Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways
    Sakae Tanaka · 2013 · World Journal of Orthopedics
  7. Selective Targeting of RANK Signaling Pathways as New Therapeutic Strategies for Osteoporosis
    J. Jules, Jason W. Ashley, Xu Feng · 2010 · Expert opinion on therapeutic targets
  8. Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology
    Philippe K. Zysset, Dieter H. Pahr, Klaus Engelke, Harry K. Genant, Michael R. McClung, David L. Kendler, Christopher P. Recknor, Michael Kinzl, Jakob J. Schwiedrzik, Oleg Museyko et al. · 2015 · Bone
  9. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer
    Stefan Julia Kiechl, Daniel Schramek, Martin Widschwendter, Evangelia-O Fourkala, Alexey A. Zaikin, Allison Jones, Bernadette AS Jaeger, Brigitte Kathrin Rack, Wolfgang J. Janni, Christoph Scholz et al. · 2016 · Oncotarget
  10. Bacteria, Bones, and Stones: Managing Complications of Short Bowel Syndrome
    Erika Johnson, Long Vu, Laura E. Matarese · 2018 · Nutrition in Clinical Practice
  11. Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots
    Yuanyu Qiu, Wu Yang, Qijin Wang, Sijia Yan, Bo Li, Xiao Zhai · 2018 · Archives of Osteoporosis
  12. Multiple actions of parathyroid hormone‐related protein in breast cancer bone metastasis
    Thomas John Martin, Rachelle W. Johnson · 2019 · British Journal of Pharmacology
  13. Effects of bisphosphonates on osteoporosis: Focus on zoledronate
    Ahmad Oryan, Sonia Sahvieh · 2020 · Life Sciences
  14. Impact of 3D cell culture on bone regeneration potential of mesenchymal stromal cells
    Mesude Biçer, Graeme Stuart Cottrell, Darius Widera · 2021 · Stem Cell Research & Therapy
  15. The Role of PINP in Diagnosis and Management of Metabolic Bone Disease
    Melissa J Gillett, Samuel D Vasikaran, Charles Anoopkumar Inderjeeth · 2021 · Clinical Biochemist Reviews
  16. The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density
    Anna C. van der Burgh, Catherine E. de Keyser, M. Carola Zillikens, Bruno H. Ch. Stricker · 2021 · Drugs
  17. Bone fragility and osteoporosis in children and young adults
    Melissa M. Formosa, María Christou, Outi Mäkitie · 2023 · Journal of Endocrinological Investigation
  18. Bone Targeting Nanoparticles for the Treatment of Osteoporosis
    Caining Wen, Xiao Min Xu, Yuanmin Zhang, Jiang Xia, Yujie Liang, Limei Xu · 2024 · International Journal of Nanomedicine
  19. Parkinson's disease: A risk factor for osteoporosis
    Sandrine Malochet‐Guinamand, Franck Durif, Thierry Thomas · 2015 · Joint Bone Spine
  20. Atypical femoral fractures bilaterally in a patient receiving denosumab
    Efstathios Drampalos, George A. Skarpas, Nikos Barbounakis, Ioannis Michos · 2013 · Acta Orthopaedica
  21. Oral salmon calcitonin – pharmacology in osteoporosis
    Kim Henriksen, Anne‐Christine Bay‐Jensen, Claus Christiansen, M.A. Karsdal · 2010 · Expert Opinion on Biological Therapy
  22. Current, new and future treatments of osteoporosis
    Pooneh Salari, Mohammad Reza Abdollahi, Bagher A. Larijani · 2010 · Rheumatology International
  23. Using GWAS to identify novel therapeutic targets for osteoporosis
    Olivia L. Sabik, Charles R. Farber · 2016 · Translational research
  24. Osteoclast regulation of osteoblasts via RANK-RANKL reverse signal transduction in vitro
    Shiqian Zhang, Xiaoyu Wang, Guojun Li, Yang Chong, Jie Zhang, Xinzhen Guo, Baoxin Li, Zhenggang Bi · 2017 · Molecular Medicine Reports
  25. Osteoporosis Therapy With Denosumab in Organ Transplant Recipients
    Jana Brunova, Simona Kratochvílová, Jitka Štěpánková · 2018 · Frontiers in Endocrinology
  26. RANKL as a therapeutic target of rheumatoid arthritis
    Sakae Tanaka, Yoshiya Tanaka · 2020 · Journal of Bone and Mineral Metabolism
  27. RETIRED: Osteoporosis in Menopause
    Aliya Aziz Khan, Michel P. Fortier, Michel P. Fortier, Robert L. Reid, Beth L. Abramson, Jennifer M. Blake, Sophie Desindes, Sylvie Dodin, Lisa E. Graves, Bing Guthrie et al. · 2014 · Journal of Obstetrics and Gynaecology Canada · Retracted
  28. Bridging the Osteoporosis Treatment Gap: Performance and Cost-Effectiveness of a Fracture Liaison Service
    Christopher James Yates, Marie-Anne Chauchard, Danny Liew, Andrew Bucknill, John Dennis Wark · 2015 · Journal of Clinical Densitometry
  29. Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy
    Anna Diana, Francesca Carlino, Emilio Francesco Giunta, Elisena Franzese, Luigi Pio Guerrera, Vincenzo Di Lauro, Fortunato Ciardiello, Bruno Daniele, Michele Orditura · 2021 · Current Treatment Options in Oncology
  30. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women
    Barry S. Komm, Diana Morgenstern, Luis A. Yamamoto, Simon N Jenkins · 2015 · Expert Review of Clinical Pharmacology
  31. Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
    T. Nakamura, Toshio Matsumoto, Toshitsugu Sugimoto, Masataka Shiraki · 2011 · Osteoporosis International
  32. Inhaled Corticosteroids and Bone Health
    Carolyn Chee, Luckni Sellahewa, Joseph M Pappachan · 2015 · The Open Respiratory Medicine Journal
  33. Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis
    Antonino Lasco, Nunziata Morabito, Giorgio Basile, Marco Atteritano, Agostino Gaudio, Grazia Maria Giorgianni, Elisabetta Morini, Bianca Faraci, Federica Bellone, Antonino Catalano · 2015 · Calcified Tissue International
  34. Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw
    Steven J. Caldroney, Naseem Ghazali, Donita Dyalram, Joshua Eli Lubek · 2017 · International Journal of Oral and Maxillofacial Surgery
  35. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium
    Astrid Fahrleitner‐Pammer, Νικόλαος Παπαϊωάννου, Evelien Gielen, Maurille Feudjo Tepie, C. Toffis, Isolde Frieling, Piet Geusens, Polyzois Makras, Ewald Boschitsch, J. Callens et al. · 2017 · Archives of Osteoporosis
  36. Therapeutic ionizing radiation induced bone loss: a review of in vivo and in vitro findings
    Jian Zhang, Xinyu Qiu, Kedi Xi, Wentao Hu, Hailong Pei, Jing Nie, Ziyang Wang, Jia-Han Ding, Peng Shang, Bingyan Li et al. · 2018 · Connective Tissue Research
  37. Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons
    Jin‐Woo Kim, Mi Kyung Kwak, Jeong Joon Han, Sung‐Tak Lee, Ha Young Kim, Se Hwa Kim, Junho Jung, Jeong Keun Lee, Young‐Kyun Lee, Yong‐Dae Kwon et al. · 2021 · Journal of Bone Metabolism
  38. Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation
    Qiang Fu, Nancy Cecile Bustamante-Gomez, Humberto Reyes-Pardo, Igor B. Gubrij, Diana Escalona‐Vargas, Jeff D. Thostenson, Michela Palmieri, Joseph J. Goellner, Intawat Nookaew, Charles Lowry Barnes et al. · 2023 · JCI Insight
  39. Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis
    Jeffrey R. Curtis, Tarun Arora, Ye Liu, Tzu‐Chieh Lin, Leslie Spangler, Vanessa C. Brunetti, Robert Kees Stad, Michele McDermott, Brian D. Bradbury, Min Kim · 2024 · Journal of Bone and Mineral Research
  40. Treatment of osteoporosis after alendronate or risedronate
    Pia Eiken, Peter Vestergaard · 2015 · Osteoporosis International
  41. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury
    Laia Gifre, Joan Vidal, Josep L. Carrasco, África Muxí, Enric Portell, Ana Monegal, Núria Guañabens, Pilar Peris · 2015 · Osteoporosis International
  42. Update on Menopausal Hormone Therapy for Fracture Prevention
    Jan J. Stepan, Hana Hruskova, Miloslav Kverka · 2019 · Current Osteoporosis Reports
  43. Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study
    Chien‐Liang Chen, N. C. Chen, Fu‐Zong Wu, Ming-Ting Wu · 2020 · Osteoporosis International
  44. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study
    Tomonori Kobayakawa, Takako Suzuki, Masaki Nakano, Makoto Saito, Akiko Miyazaki, Jun A. Takahashi, Yukio Nakamura · 2021 · Bone Reports
  45. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
    Jacques P. Brown, Christian Roux, Pei‐Ran Ho, Michael A. Bolognese, Jesse W. Hall, Henry G. Bone, Sydney Lou Bonnick, Joop P. van den Bergh, I. Ferreira, Paula Dakin et al. · 2014 · Osteoporosis International
  46. Effects of Antiepileptic Drugs on Bone Health and Growth Potential in Children with Epilepsy
    Peter Vestergaard · 2015 · Pediatric Drugs
  47. Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
    José Luis Pérez‐Castrillón, Florentino Pinacho, Daniel Antonio de Luis, María López-Menéndez, Antonio Dueñas‐Laita · 2010 · Journal of Osteoporosis
  48. Management of osteoporosis in patients hospitalized for hip fractures
    Tai‐Pang Ip, J. Leung, Annie W.C. Kung · 2010 · Osteoporosis International
  49. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion
    Guenther G. Steger, Rupert Bartsch · 2011 · Therapeutic Advances in Medical Oncology
  50. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis
    M. A. Amiche, Jordan M. Albaum, Mina Tadrous, Petros Pechlivanoglou, Linda E. Lévesque, Jonathan Derrick Adachi, Suzanne M. Cadarette · 2016 · Osteoporosis International
  51. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab
    Akihiko Matsumoto, Masanori Sasaki, Rainer Schmelzeisen, Yukiko OOYAMA, Yoshihide Mori, Pit Jacob Voss · 2016 · Clinical Oral Investigations
  52. Bone and Mineral Metabolism
    Juha Risteli, William E. Winter, Michael Kleerekoper, Leila Risteli · 2012 · Elsevier eBooks
  53. Cytokine profiles in osteoporosis suggest a proresorptive bias
    F. Azizieh, R. Raghupathy, D. Shehab, K. Al-jarallah, Renu Gupta · 2017 · Menopause
  54. Monoclonal antibodies for treating osteoporosis
    Maria Felicia Faienza, Mariangela Chiarito, Gabriele D’Amato, Graziana Colaianni, Silvia Concetta Colucci, Maria Grano, Giacomina Brunetti · 2017 · Expert Opinion on Biological Therapy
  55. New Insights for RANKL as a Proinflammatory Modulator in Modeled Inflammatory Arthritis
    Maria E. Papadaki, Vagelis E. Rinotas, Foteini Violitzi, Trias N. Thireou, George Panayotou, Martina K. Samiotaki, Eleni K. Douni · 2019 · Frontiers in Immunology
  56. The effects of adjuvant endocrine therapy on bone health in women with breast cancer
    Sabashini K. Ramchand, Yee-Ming Melody Cheung, Belinda Jane Yeo, Mathis Grossmann · 2019 · Journal of Endocrinology
  57. Denosumab for dialysis patients with osteoporosis: A cohort study
    Kyohei Kunizawa, Rikako Hiramatsu, Junichi Hoshino, Hiroki Mizuno, Yuko Ozawa, Akinari Sekine, Masahiro Kawada, Keiichi Sumida, Eiko Hasegawa, Masayuki Yamanouchi et al. · 2020 · Scientific Reports
  58. New treatment targets in osteoporosis
    Sophie Roux · 2010 · Joint Bone Spine
  59. Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
    Albert Sungsoo Kim, Christian M. Girgis, Michelle Maree McDonald · 2022 · Current Osteoporosis Reports
  60. Receptor activator of nuclear factor kappa B ligand antagonists inhibit tissue inflammation and bone loss in experimental periodontitis
    Huaiping Yuan, Rohit K. Gupte, Sami Zelkha, Salomon Amar · 2011 · Journal Of Clinical Periodontology
  61. Efficacy and safety of currently marketed anti-osteoporosis medications
    Jean‐Yves Reginster, Audrey Neuprez, Nadia Dardenne, Charlotte Beaudart, Patrick Emonts, Olivier Bruyère · 2014 · Best Practice & Research Clinical Endocrinology & Metabolism
  62. Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis
    Camilla von Keyserlingk, Robert Borden Hopkins, Athanasios D. Anastasilakis, Konstantinos A. Toulis, Ron A. Goeree, Jean‐Éric Tarride, Feng Xie · 2011 · Seminars in Arthritis and Rheumatism
  63. Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial
    Athanasios D. Anastasilakis, Stergios A. Pοlyzos, Athina I. Gkiomisi, Ilias Bisbinas, Spyridon Gerou, Polyzois Makras · 2013 · The Journal of Clinical Endocrinology & Metabolism
  64. Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response–Based Meta-Analysis
    Jaap W. Mandema, Jenny Zheng, Cesar R. Libanati, Juan José Pérez Ruixo · 2014 · The Journal of Clinical Endocrinology & Metabolism
  65. Effect of Single Dose of RANKL Antibody Treatment on Acute Charcot Neuro-osteoarthropathy of the Foot
    Tessa E. Busch‐Westbroek, Kamiel Delpeut, Ron Balm, Sicco A. Bus, Tim Schepers, Edgar J.G. Peters, Frank F. Smithuis, Mario M. Maas, Max Nieuwdorp · 2017 · Diabetes Care
  66. Influence of geometry on proximal femoral shaft strains: Implications for atypical femoral fracture
    Ifaz T. Haider, Prism Schneider, Andrew S. Michalski, William Brent Edwards · 2018 · Bone
  67. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density
    K.E. Naylor, Mike J Bradburn, Margaret Paggiosi, Fatma Gossiel, Nicola F. A. Peel, Eugene Vincent McCloskey, Jennifer Walsh, Richard Eastell · 2018 · Osteoporosis International
  68. Adding Lateral Spine Imaging for Vertebral Fractures to Densitometric Screening: Improving Ascertainment of Patients at High Risk of Incident Osteoporotic Fractures
    Richard Lewis Prince, Joshua Richard Lewis, Wai H. Lim, Germaine Wong, Kevin E. Wilson, Benjamin Cheng Choon Khoo, Kun Zhu, Douglas P. Kiel, John T. Schousboe · 2018 · Journal of Bone and Mineral Research
  69. RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease
    Biagio Palmisano, Emanuela Spica, Cristina Remoli, Rossella Labella, Annamaria Di Filippo, Samantha Donsante, Fabiano Bini, Domenico Raimondo, Franco Marinozzi, ALAN BOYDE et al. · 2019 · Journal of Bone and Mineral Research
  70. Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position
    David L. Kendler, Juliet Elizabeth Compston, JOHN J. CAREY, Chih‐Hsing Wu, Ammar Ibrahim, Edward Michael Lewiecki · 2019 · Journal of Clinical Densitometry
  71. JNK1 regulates RANKL‐induced osteoclastogenesis via activation of a novel Bcl‐2‐Beclin1‐autophagy pathway
    Dianshan Ke, Lianmei Ji, Yu Wang, Xiaomin Fu, Jinyan Chen, Fan Wang, Dongbao Zhao, Ying Xue, Xu-hua Lan, Jianming Hou · 2019 · The FASEB Journal
  72. Osteoporosis
    Mark S. Nanes, Caleb B. Kallen · 2014 · Seminars in Nuclear Medicine
  73. Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
    Meghna Jani, Anne C Barton, Kimme Leanne Hyrich · 2019 · Current Opinion in Rheumatology
  74. New perspectives on the treatment of skeletal dysplasia
    Pauline Marzin, Valérie Cormier‐Daire · 2020 · Therapeutic Advances in Endocrinology and Metabolism
  75. Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer
    Michael Gnant, Sophie Frantal, Georg Pfeiler, Guenther G. Steger, Daniel Egle, Richard Greil, Florian Fitzal, Viktor Wette, Marija Balić, Ferdinand Haslbauer et al. · 2022 · NEJM Evidence
  76. Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial
    Andrew B. Grey, Mark J Bolland, Sumwai Wong, Anne M. Horne, Greg D. Gamble, Ian R. Reid · 2011 · The Journal of Clinical Endocrinology & Metabolism
  77. New and Emerging Therapies for Bone Metastases in Genitourinary Cancers
    Philip James Saylor, Andrew J. Armstrong, Karim S. Fizazi, Stephen J. Freedland, Fred Saad C, Matthew R. Smith, Bertrand F. TOMBAL, Kenneth J. Pienta · 2012 · European Urology
  78. Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?
    Mark J Bolland, Andrew B. Grey, Ian R. Reid · 2015 · Climacteric
  79. Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club
    Evelien Gielen, P. Bergmann, Olivier Bruyère, Etienne Cavalier, Pierre Delanaye, Stefan Goemaere, Jean‐Marc Kaufman, Médéa Locquet, Jean‐Yves Reginster, Serge Rozenberg et al. · 2017 · Calcified Tissue International
  80. Utility of DXA for monitoring, technical aspects of DXA BMD measurement and precision testing
    JOHN J. CAREY, Miriam F. Delaney · 2017 · Bone
  81. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis
    Lanling Zhang, Yafei Pang, Yeqing Shi, Meijuan Xu, Xia Xu, Zhang Ju, Lianmei Ji, Dongbao Zhao · 2015 · Menopause The Journal of The North American Menopause Society
  82. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates
    Liana Tripto‐Shkolnik, Vanessa Rouach, Yonit Marcus, Pnina Rotman‐Pikielny, Carlos A. Benbassat, Iris Vered · 2018 · Calcified Tissue International
  83. Updates in CKD-Associated Osteoporosis
    Pascale Khairallah, Thomas L. Nickolas · 2018 · Current Osteoporosis Reports
  84. Rethinking Bone Disease in Kidney Disease
    Matthew J. Damasiewicz, Thomas L. Nickolas · 2018 · JBMR Plus
  85. Romosozumab: A Review in Postmenopausal Osteoporosis
    Julia Paik, Lesley J. Scott · 2020 · Drugs & Aging
  86. Abaloparatide: A review of preclinical and clinical studies
    Mikkel Bo Brent · 2021 · European Journal of Pharmacology
  87. Targeting RANKL in breast cancer: bone metastasis and beyond
    Hamdy A. Azim, Hatem A. Azim · 2013 · Expert Review of Anticancer Therapy
  88. Atypical femoral fracture in a patient treated with denosumab
    Kareeann S.F. Khow, Tuck Yean Yong · 2014 · Journal of Bone and Mineral Metabolism
  89. Recent developments in osteogenesis imperfecta
    Joseph L. Shaker, Carolyne Albert, Jessica M. Fritz, Gerald F. Harris · 2015 · F1000Research
  90. Decreased bone mineral density and periodontal management
    Michael S. Reddy, Sarah L. Morgan · 2012 · Periodontology 2000
  91. Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-Analysis
    Stewart Gary Albert, Supraja Reddy · 2017 · Endocrine Practice
  92. Oral administration of kaempferol inhibits bone loss in rat model of ovariectomy-induced osteopenia
    Beata Nowak, Agnieszka Matuszewska, Anna Nikodem, Jarosław Filipiak, Marcin Landwójtowicz, Ewa Sadanowicz, Diana Jędrzejuk, Marta Rzeszutko, Krzysztof Zduniak, Tomasz Piasecki et al. · 2017 · Pharmacological Reports
  93. Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization
    Javier Martínez‐Reina, Peter Pivonka · 2019 · Bone
  94. Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview
    Yoshiya Tanaka · 2021 · Journal of Clinical Medicine
  95. Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?
    Yasser M El Miedany, Maha Mohamed El Gaafary, Mathias Toth, Mohamed Osama Hegazi, Nadia El Aroussy, Waleed Ahmed Hassan, S. Almedany, Annie Nasr, Sami M. Bahlas, Salwa Galal · 2021 · Clinical Rheumatology
  96. Pathogenesis and Treatment of Myeloma-Related Bone Disease
    Yuh-Ching Gau, Tsung-Jang Yeh, Chin-Mu Hsu, S. Y. Hsiao, Hui-Hua Hsiao · 2022 · International Journal of Molecular Sciences
  97. The longitudinal effects of ovariectomy on the morphometric, densitometric and mechanical properties in the murine tibia: A comparison between two mouse strains
    Bryant C. Roberts, Mario Giorgi, Sara Oliviero, Ning Wang, Maya Boudiffa, Enrico Dall’Ara · 2019 · Bone
  98. Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk
    Richard Eastell, Eric Vittinghoff, Li‐Yung Lui, Susan K. Ewing, Ann V. Schwartz, Douglas C. Bauer, Dennis M. Black, Mary Bouxsein · 2020 · Journal of Bone and Mineral Research
  99. A Comprehensive Review on Postmenopausal Osteoporosis in Women
    Samruddhi H Charde, Abhishek Joshi, Juhi Mangesh Raut · 2023 · Cureus
  100. Treatment of primary osteoporosis in men
    Geralamo Bianchi, Andrea Giusti · 2014 · Clinical Interventions in Aging